Board of Directors
Ms. Levy has over 27 years of business experience in biotechnology, including new product assessment, strategy and business development as a consultant, and in management roles with the Diagnostics Divisions of Abbott Laboratories and Genzyme Corporations. While at Genzyme, she managed the early development of Ceredase® for the treatment of Gaucher's Disease and participated in the successful raising of the R&D limited Partnership to fund the drug's development. She was responsible for global business unit product management for immunoassay, CNS diagnostics, high-volume automation and data management products at Abbott. Since 1992, Ms. Levy has been consulting to pharmaceutical and biotechnolgoy companies, venture capital firms and academic institutions. She has also played an active role as an investor for a corporate life science venture fund of a healthcare system. In these roles, she has been involved in the due diligence, start up and growth of new ventures and corporate product developement programs in clinical diagnostics and personalized medicine, new ressearch tools, stem cells and new biologics and pharmaceuticals. She served on the Board of Directors and as an Officer of HBS Health, a network of Harvard Business School alumni in healthcare. Ms. Levy currently serves on the Board of the Association for Frontotemporal Degeneration and co-founded the Boston area support group for caregivers of patients with these disorders.
Ms. Levy holds an MBA from the Harvard Business School and a BA in Chemistry from Swarthmore College.
Dr. Aggarwal is chief executive officer of Instant Medical Diagnostics, an early stage company developing point of care diagnostic instruments, and managing partner of the Channel Group, a strategic and capital advisory organization. Dr. Aggarwal has over 30 years of experience in both pharmaceutical services and clinical diagnostics. Prior to joining Instant Medial Diagnostics, he served as president and chief executive officer of Aureon Laboratories, a laboratory that served the urology community; President of AAI Development Services, a contract research organisation and President of Quest Diagnostic Ventures, a division of Quest Diagnostics. In addition to Mitomics, Dr. Aggarwal currently serves on the boards of several privately held diagnostic testing companies, including Accugenomics, Hycore Biomedical Inc., Viracore-IBT Laboratories and Genisphere Inc.
He earned a Ph.D. in pharmacology/toxicology from the Medical College of Virginia and has his B.A. from Case Western Reserve University, Cleveland, Ohio.
Mr. Fallon was a director and Chairman of the Board of Osteotech Inc. (NASDAQ), until it was sold to Medtronic Inc. in 2010. He has over 40 years of experience in the medical device industry marked with success in leadershiop and innovation within organizations ranging from venture backed start-ups to fully integrated market leaders. Mr. Fallon was president of US Operations for Zimmer Inc., the world's largest orthopaedic company. He served as Chairman and CEO of Axya, Inc. At Haemonetics Inc., he was president of the Surgical Business Unit and served as Chairman and CEO for UltraCision Inc., until it was sold to Johnson and Johnson Inc. He was also president and CEO of Americal Surgical Technologies Corporation.
Mr. Fallon has a B.B.A. degree in marketing from the University of Massachusetts and an M.B.A. degree from Northeastern University.
Mr. Galliker currently serves as a member of the board of directors of Galena Biopharma, Inc., a biopharmaceutical company focused on developing innovative, targeted oncology treatments; and he previously served as a director of Osteotech, Inc. (now Medtronic, Inc.), an innovator in biologic, biomaterial and device systems for muscoskeletal surgery. He brings more than 40 years' experience in finance and accounting to the Mitomics board of directors. Most recently, Mr. Galliker was chief financial officer and executive vice president of finance and administration at Dyax Corp, a biopharmaceutical company, where he oversaw all aspects of financial and operational reporting, human resources, investor relations and information technology until his retirement in 2008. Prior to that, Mr. Galliker served as chief financial officer and in other senior operating positions at a variety of technology and medical product companies including Excel Switching Corp.; UltraCision, Inc.; Tylink Communications/Avanti Communications; Community Care Systems, Inc.; and Sippican, Inc.
He is a certified public accountant and received a B.S. from Georgetown University and an M.B.A. from the University of Chicago Graduate School of Business.
Mr. Poulter joined Mitomics in 2007 to oversee the company's transition from a research and development position to the successful commercialization of its products. Previously, he served as the practice leader for IBM's business consulting division, where he was in charge of the diverse and dynamic markets of Southeast Asia and India. While at IBM, his focus was in the fast-growing area of Customer Relationship Management (CRM), in which he was responsible for building the company's CRM practice from infancy to a multi-million dollar business. His extensive business background includes senior executive experience in finance, business strategy, and mergers and acquisitions, with various high-level management positions within Accenture and the Royal Bank of Canada. Mr. Poulter’s vast experience includes sales, marketing, commercial development and management in various markets, including Canada, United States, Europe and Southeast Asia.
He received an HBComm in marketing and finance from Lakehead University.
Currently a non-executive director and private investor in a number of companies, Mr. Smart has worked in both the public and private sectors and has established a track record of successfully taking companies and organizations through major strategic changes. Over the last 15 years he has been involved as an executive director and shareholder in two management buyouts and two company startups, and was instrumental in the successful growth and sale of the enterprises at significant gains for shareholders. In addition, Mr. Smart has lectured at universities and management institutions and has authored numerous papers and articles.
Mr. Smart holds a B.Sc. in chemical technology, a B.A. in applied computing, as well as an M.B.A. from the University of Newcastle upon Tyne.
Dr. Thayer, a Mitomics co-founder, is a former professor of kinesiology, adjunct professor of biology and faculty member in the applied biomolecular science program at Lakehead University in Thunder Bay, Ontario. Collectively, he has 27 years of teaching experience in kinesiology and biochemistry. His research focused on heat shock protein expression in skeletal muscle from elderly subjects and mtDNA mutation associated with aging, skin and prostate cancer. Throughout his career, Dr. Thayer has authored 52 peer-reviewed publications, book chapters and abstracts. In addition to his academic career, he was a former Olympic athlete and coach for the Canadian Olympic Team in the 1976 Montreal Games and the 1980 Moscow Games.
Dr. Thayer received his Ph.D. in kinesiology and biochemistry from the University of Western Ontario.
